Trial Profile
Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine Bone Mineral Density in Men and Postmenopausal Women with Low Bone Mass and a Recent Pertrochanteric Hip Fracture
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jan 2022
Price :
$35
*
At a glance
- Drugs Teriparatide (Primary) ; Risedronic acid
- Indications Bone resorption; Male osteoporosis; Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms MOVE
- Sponsors Eli Lilly and Company
- 12 Oct 2015 Efficacy analysis (n=171) and 26 weeks interim results was presented at the 37th Annual Meeting of the American Society for Bone and Mineral Research
- 04 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.